Franck Bourdeaut is a pediatric oncologist currently working at Institut Curie with two main fields of clinical practice: pediatric neuro-oncology and genetic predisposition to childhood cancer.
In neuro-oncology, Franck Bourdeaut is more particularly involved in pediatric embryonic brain tumors, and presently coordinate the French working sub-group for these entities. He is also the current chair of the European ATRT working group within SIOPe. He has been the French principal investigator of two international Phase I-II trials recruiting patients with SMARCB1-deficient cancers and will be the French principal Investigator of the next European prospective protocol for children with newly diagnosed ATRT. His is also a member of SIOPe Medulloblastoma working group, particularly in charge for France of the development of molecular diagnosis and genetic assesments.
In the field of genetic predisposition, he has co-funded and chaired the French Committee of Oncogenetics for 10 years and is now an elected member of the steering committee of the European group working on predisposition to childhood cancers (SIOPe Host Genome Working Group). He is also a co-funder and member of the pilot committee of the national observatoire for cancer pediatric predispositions syndromes (PREDCAP).
Franck Bourdeaut is also heading a research team dedicated to Smarcb1-deficiency in cancer, and mainly focusing on rhabdoid tumors, within the Translational Research In Pediatric Oncology Lab (INSERM U830 directed by Dr Olivier Delattre). His main interests include i) the development of various mouse models of Smarcb1-deficiency, to elucidate early oncological events and to give access to relevant preclinical tools, and ii) combination of innovative therapies, focusing in particular on immunotherapy and epidrugs.
He has been a recipient of the “Interface INSERM pour hospitaliers” grant, and the SIOP/Arceci innovation Award in 2016.